CGPHF (Grand Pharmaceutical Group) Total Assets: $3,491.52 Mil (As of Dec. 2025)


What is Grand Pharmaceutical Group Total Assets?

Grand Pharmaceutical Group CGPHF 86 Total Assets is $3,491.52 Mil as of Dec. 2025. GuruFocus rates CGPHF with a GF Score™ of 86/100. The stock has 6 warning signs investors should review.

Grand Pharmaceutical Group's Total Assets for the quarter that ended in Dec. 2025 was $3,491.52 Mil.

During the past 12 months, Grand Pharmaceutical Group's average Total Assets Growth Rate was 14.90% per year. During the past 3 years, the average Total Assets Growth Rate was 8.10% per year. During the past 5 years, the average Total Assets Growth Rate was 9.80% per year. During the past 10 years, the average Total Assets Growth Rate was 15.90% per year.

During the past 13 years, Grand Pharmaceutical Group's highest 3-Year average Total Assets Growth Rate was 119.00%. The lowest was -13.90%. And the median was 25.20%.

Total Assets is connected with ROA %. Grand Pharmaceutical Group's annualized ROA % for the quarter that ended in Dec. 2025 was 0.54%. Total Assets is also linked to Revenue through Asset Turnover. Grand Pharmaceutical Group's Asset Turnover for the quarter that ended in Dec. 2025 was 0.23.

Grand Pharmaceutical Group  (OTCPK:CGPHF) Total Assets Explanation

Total Assets is connected with ROA %.

Grand Pharmaceutical Group's annualized ROA % for the quarter that ended in Dec. 2025 is

ROA %=Net Income (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=18.47/( (3372.248+3491.518)/ 2 )
=18.47/3431.883
=0.54 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Grand Pharmaceutical Group's Asset Turnover for the quarter that ended in Dec. 2025 is

Asset Turnover
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=793.742/( (3372.248+3491.518)/ 2 )
=793.742/3431.883
=0.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Grand Pharmaceutical Group Total Assets Related Terms

Grand Pharmaceutical Group Total Assets Historical Data

* Premium members only.

The historical data trend for Grand Pharmaceutical Group's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grand Pharmaceutical Group Total Assets Chart

Grand Pharmaceutical Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,699.97 2,873.46 2,882.96 3,214.96 3,491.52

Grand Pharmaceutical Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,882.96 3,188.48 3,214.96 3,372.25 3,491.52

Grand Pharmaceutical Group Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Grand Pharmaceutical Group's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=2207.959+1283.559
=3,491.52

Grand Pharmaceutical Group's Total Assets for the quarter that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (Q: Dec. 2025 )+Total Liabilities (Q: Dec. 2025 )
=2207.959+1283.559
=3,491.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $3,491.52 Mil mean?
Grand Pharmaceutical Group (CGPHF) has a Total Assets of $3,491.52 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Grand Pharmaceutical Group and its competitors.
Is Grand Pharmaceutical Group's Total Assets too high?
Grand Pharmaceutical Group's current Total Assets is $3,491.52 Mil. Overall, Grand Pharmaceutical Group has a GF Score™ of 86/100, reflecting its overall financial health beyond just this single metric.
How does Grand Pharmaceutical Group's Total Assets compare to ZTS and UTHR?
Grand Pharmaceutical Group's Total Assets of $3,491.52 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Grand Pharmaceutical Group and its competitors. Grand Pharmaceutical Group's current Total Assets is $3,491.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grand Pharmaceutical Group stock overvalued right now?
Grand Pharmaceutical Group (CGPHF) has a current Total Assets of $3,491.52 Mil. The current Total Assets is $3,491.52 Mil. Grand Pharmaceutical Group's overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Grand Pharmaceutical Group (CGPHF), the current Total Assets is $3,491.52 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Grand Pharmaceutical Group Business Description

Other Exchanges 00512:Hong KongMX6A:Germany
Address 99 Queen\'s Road Central, Units 3302, 33rd Floor, The Center, Hong Kong, HKG
Grand Pharmaceutical Group Ltd are principally engaged in the manufacture and sales of pharmaceutical technology products, manufacture and sales of bio-technology products as well as manufacture and sales of nuclear medicine anti-tumor diagnosis and treatment and cerebro-cardiovascular precision interventional diagnosis and treatment technology products, in the People's Republic of China. The operation of the group constitutes one single reportable segment. The company has presence in The PRC, America, Europe, Asia other than the PRC and Others. The majority of revenue comes from the PRC. Its brands are breathe, biology, Cardiovascular emergency care, Cardiovascular intervention, ENT, tumor.